Mycobacterium Complex - PCR (Tissue)

Mycobacterial PCR is a molecular test that detects DNA from mycobacteria (for example Mycobacterium tuberculosis and non‑tuberculous mycobacteria) in clinical specimens. It uses polymerase chain reaction to amplify specific genetic sequences, giving faster, more sensitive and specific results than culture. It can be performed on sputum, tissue or body fluids and some assays also identify drug‑resistance mutations with results in hours to days.

"MTB PCR positive" means a molecular test detected Mycobacterium tuberculosis DNA in a clinical specimen, indicating probable active tuberculosis. PCR is rapid and sensitive but can detect nonviable bacteria after treatment, so results must be interpreted with symptoms, imaging, and culture. Many PCR assays also assess rifampicin resistance to guide appropriate therapy.

Yes. PCR can be performed on tissue by extracting DNA or RNA first. Fresh or frozen tissue gives the best nucleic acid quality, but formalin-fixed paraffin-embedded (FFPE) tissue can also be used with specialized extraction methods. RT‑PCR detects RNA (e.g., viruses) and PCR detects DNA; processing and fixation can reduce yield, so careful extraction, controls, and appropriate assays are required.

A positive TB PCR indicates detection of Mycobacterium tuberculosis DNA and strongly suggests active tuberculosis. Clinicians will correlate with symptoms and chest imaging, perform confirmatory tests (culture and drug‑susceptibility testing; molecular rifampicin resistance testing), start appropriate anti‑TB treatment promptly, implement infection control/isolation for pulmonary cases, notify public health, and evaluate close contacts and HIV status.

PCR for TB stands for polymerase chain reaction testing that detects DNA of Mycobacterium tuberculosis complex in clinical specimens. It is a rapid molecular diagnostic method more sensitive than smear microscopy, able to identify small numbers of bacteria and often detect genetic markers of drug resistance (e.g., rifampicin). Results support early diagnosis and treatment decisions, but culture and clinical correlation remain important.

Diagnosis combines clinical assessment and targeted testing: relevant history and exam, chest imaging (X‑ray/CT), microbiology with acid‑fast bacilli smear and culture, and nucleic acid amplification tests (e.g., PCR or rapid molecular assays) for detection. Latent infection uses tuberculin skin testing or interferon‑gamma release assays. Tissue biopsy/histopathology and drug‑susceptibility testing guide management for confirmed mycobacterial disease.